Basic Information
| Drug ID | DDPD00683 |
|
| Drug Name | Midazolam | |
| Molecular Weight | 325.767 | |
| Molecular Formula | C18H13ClFN3 | |
| CAS Number | 59467-70-8 | |
| SMILES | CC1=NC=C2CN=C(C3=CC=CC=C3F)C3=C(C=CC(Cl)=C3)N12 | |
| External Links | ||
| DRUGBANK | DB00683 | |
| T3DB | T3D2859 | |
| PubChem Compound | 4192 | |
| PDR | 1837 | |
| Drugs.com | Drugs.com Drug Page | |
Experimental Physicochemical Property
| Property Name | Property Value | Unit | Raw Value | Raw Unit | Reference |
|---|---|---|---|---|---|
| Boiling Point | 497.0 | ℃ | 497 | ℃ | MSDS |
| Melting Point | 162.5 | ℃ | 161-164 | ℃ | MSDS |
Pharmacokinetic/ Toxicokinetic Property
| Property Name | Property Value | Unit | Raw Value | Raw Unit | Annotation | Factor | Reference |
|---|---|---|---|---|---|---|---|
| Bioavailability | 90.0 | % | >90 | % | IM,intramuscular injection; | DRUGBANK | Bioavailability | 45.0 | % | 40-50 | % | PO, oral; | DRUGBANK | Bioavailability | 36.0 | % | 36 | % | pediatric patients; | DRUGBANK | Bioavailability | 50.0 | % | 50 | % | Rectal Administration; | DRUGBANK | Bioavailability | 56.0 | % | 55-57 | % | inhalation, IH; | DRUGBANK | Bioavailability | 44.0 | % | 44±17 | % | PO, oral; | The Pharmacological Basis of Therapeutics |
| C Max | 90.0 | ng/ml | 90.0 | ng/ml | IM,intramuscular injection; | DRUGBANK | C Max | 78.0 | ng/ml | 78±27 | ng/ml | Oral single dose; | The Pharmacological Basis of Therapeutics | C Max | 113.0 | ng/ml | 113±16 | ng/ml | The Pharmacological Basis of Therapeutics |
| T Max | 0.50 | h | 0.5 | h | IM,intramuscular injection; | DRUGBANK | T Max | 0.50 | h | 0.5 | h | Rectal Administration; | DRUGBANK | T Max | 0.19 | h | 10.2-12.6 | min | inhalation, IH; | DRUGBANK | T Max | 0.67 | h | 0.67±0.45 | h | Oral single dose; | The Pharmacological Basis of Therapeutics |
| Clearance | 22.0 | L/h/kg | 367.3±73.5 | ml/min/kg | Total clearance; IM,intramuscular injection; | DRUGBANK | Clearance | 0.40 | L/h/kg | 0.25-0.54 | L/h/kg | Total clearance; intravenous injection, IV; | DRUGBANK | Clearance | 0.40 | L/h/kg | 6.6±1.8 | ml/min/kg | hydrolysis; | Neonates ↓ ;Children → ;Hepatic cirrhosis, cirr ↓ ;RD, renal impairment, Renal disease，including uremia ↑ ;Obesity → ;Somking → ; | The Pharmacological Basis of Therapeutics | Clearance | 0.32 | L/h/kg | 5.3 | ml/min/kg | intravenous injection, IV; human, homo sapiens; | Human Intravenous Pharmacokinetic Dataset |
| Volume of Distribution | 1.7 | L/kg | 1.24-2.2 | L/kg | intravenous injection, IV; pediatric patients; | Female, women ↑ ;Elderly ↑ ;Obesity ↑ ; | DRUGBANK | Volume of Distribution | 2.1 | L/kg | 1-3.1 | L/kg | intravenous injection, IV; normal,healthy; adults; | DRUGBANK | Volume of Distribution | 2.1 | L/kg | 2117±845.1 | ml/kg | Average volume of distribution; IM,intramuscular injection; Single dose; normal,healthy; adults; | DRUGBANK | Volume of Distribution | 1.1 | L/kg | 1.1±0.6 | L/kg | Neonates ↓ ;Hepatic cirrhosis, cirr → ;Obesity ↑ ; | The Pharmacological Basis of Therapeutics | Volume of Distribution | 1.1 | L/kg | 1.1 | L/kg | intravenous injection, IV; human, homo sapiens; | Human Intravenous Pharmacokinetic Dataset |
| Half-life | 3.0 | h | 3(1.8-6.4) | h | intravenous injection, IV; normal,healthy; adults; | DRUGBANK | Half-life | 4.2 | h | 4.2 | h | elimination half-life; IM,intramuscular injection; | DRUGBANK | Half-life | 1.9 | h | 1.9±0.6 | h | Obesity ↑ ;Hepatic cirrhosis, cirr ↑ ;Age ↑ ;Somking → ; | The Pharmacological Basis of Therapeutics | Half-life | 3.1 | h | 3.1 | h | intravenous injection, IV; human, homo sapiens; | Human Intravenous Pharmacokinetic Dataset |
| Toxicity LD50 | 215.0 | mg/kg | 215.0 | mg/kg | Rattus, Rat; | DRUGBANK | Toxicity LD50 | 825.0 | mg/kg | 825.0 | mg/kg | PO, oral; Rattus, Rat; | T3DB |
| Eliminate Route | 0.50 | % | <0.5 | % | Urinary excretion; intravenous injection, IV; Unchanged drug; | DRUGBANK | Eliminate Route | 1.0 | % | <1 | % | Urinary excretion; Unchanged drug; | The Pharmacological Basis of Therapeutics |
| Protein Binding | 97.0 | % | 97 | % | plasma proteins; adults; human, homo sapiens; | DRUGBANK | Protein Binding | 98.0 | % | 98 | % | Elderly ↓ ;RD, renal impairment, Renal disease，including uremia ↓ ;Hepatic cirrhosis, cirr → ;Somking → ; | The Pharmacological Basis of Therapeutics |
Maximum Dosage
| Property Name | Property Value | Unit | Raw Value | Raw Unit | Annotation | Brand Name | Component | Reference |
|---|---|---|---|---|---|---|---|---|
| Max dose for infants | 1.0 | mg/kg | 1 | mg/kg | PO, oral | Midazolam Hydrochloride Syrup | midazolam hydrochloride | PDR |
| Max dose for infants | 20.0 | mg/dose | 20 | mg/dose | PO, oral | Midazolam Hydrochloride Syrup | midazolam hydrochloride | PDR |
| Max dose for infants | 0.6 | mg/kg | 0.6 | mg/kg | intravenous injection, IV | Midazolam Hydrochloride Syrup | midazolam hydrochloride | PDR |
| Max dose for infants | 6.0 | mg | 6 | mg | intravenous injection, IV | Midazolam Hydrochloride Syrup | midazolam hydrochloride | PDR |
| Max dose for children | 1.0 | mg/kg | 1 | mg/kg | PO, oral | Midazolam Hydrochloride Syrup | midazolam hydrochloride | PDR |
| Max dose for children | 20.0 | mg/dose | 20 | mg/dose | PO, oral | Midazolam Hydrochloride Syrup | midazolam hydrochloride | PDR |
| Max dose for children | 0.4 | mg/kg | 0.4 | mg/kg | intravenous injection, IV | Midazolam Hydrochloride Syrup | midazolam hydrochloride | PDR |
| Max dose for children | 10.0 | mg | 10 | mg | intravenous injection, IV | Midazolam Hydrochloride Syrup | midazolam hydrochloride | PDR |
| Max dose for children | 10.0 | mg/dose | 10 | mg/dose | nasal spray | Midazolam Hydrochloride Syrup | midazolam hydrochloride | PDR |
| Max dose for children | 1.0 | mg/kg | 1 | mg/kg | PO, oral | Midazolam Hydrochloride Syrup | midazolam hydrochloride | PDR |
| Max dose for children | 20.0 | mg/dose | 20 | mg/dose | PO, oral | Midazolam Hydrochloride Syrup | midazolam hydrochloride | PDR |
| Max dose for children | 0.4 | mg/kg | 0.4 | mg/kg | intravenous injection, IV | Midazolam Hydrochloride Syrup | midazolam hydrochloride | PDR |
| Max dose for children | 10.0 | mg | 10 | mg | intravenous injection, IV | Midazolam Hydrochloride Syrup | midazolam hydrochloride | PDR |
| Max dose for children | 1.0 | mg/kg | 1 | mg/kg | PO, oral | Midazolam Hydrochloride Syrup | midazolam hydrochloride | PDR |
| Max dose for children | 20.0 | mg/dose | 20 | mg/dose | PO, oral | Midazolam Hydrochloride Syrup | midazolam hydrochloride | PDR |
| Max dose for children | 0.6 | mg/kg | 0.6 | mg/kg | intravenous injection, IV | Midazolam Hydrochloride Syrup | midazolam hydrochloride | PDR |
| Max dose for children | 6.0 | mg | 6 | mg | intravenous injection, IV | Midazolam Hydrochloride Syrup | midazolam hydrochloride | PDR |
| Max dose for adolescents | 1.0 | mg/kg | 1 | mg/kg | PO, oral | Midazolam Hydrochloride Syrup | midazolam hydrochloride | PDR |
| Max dose for adolescents | 20.0 | mg/dose | 20 | mg/dose | PO, oral | Midazolam Hydrochloride Syrup | midazolam hydrochloride | PDR |
| Max dose for adolescents | 5.0 | mg | 5 | mg | intravenous injection, IV | Midazolam Hydrochloride Syrup | midazolam hydrochloride | PDR |
| Max dose for adolescents | 10.0 | mg/dose | 10 | mg/dose | nasal spray | Midazolam Hydrochloride Syrup | midazolam hydrochloride | PDR |
| Max dose for adults | 10.0 | mg/dose | 10 | mg/dose | nasal spray | Midazolam Hydrochloride Syrup | midazolam hydrochloride | PDR |
| Max dose for geriatric | 10.0 | mg/dose | 10 | mg/dose | nasal spray | Midazolam Hydrochloride Syrup | midazolam hydrochloride | PDR |
Drug Property Radar Chart
Note: Center: Q1-1.5*IQR, Edge: Q3+1.5*IQR; Q1: Quantile 1, Q3: Quantile 3, IQR: Q3-Q1